Get notified when PRAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $222.20 Per Share (new) — New investors pay $260.00 per share while the as adjusted net tangible book value is only $37.80, resulting in substantial immediate dilution.
Praxis Precision Medicines prices $575.1M primary offering at $260/share; net proceeds $540.1M
Filed January 7, 2026 · ~1 min read
Key Changes
-
high
Praxis is selling 2,212,000 shares at $260.00 per share in a primary offering, raising $575.1M gross before underwriting discounts.
The Offering verify on EDGAR → -
high
After underwriting discounts and estimated expenses, net proceeds to the company are approximately $540.1M.
Use of Proceeds verify on EDGAR → -
medium
Proceeds will fund commercialization preparation, R&D, and working capital; management expects cash runway into 2028.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CALM 10-Q) is open in full — no account needed.
Partner
Trade PRAX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify